Activation of Sphingomyelinase-Ceramide-Pathway in COVID-19 Purposes Its Inhibition for Therapeutic Strategies
Immunology
[키워드] Activation
adaptive
Analysis
anti-inflammatory agent
benefit
Biomarker
cellular
ceramide
circulating
circulation
clinical phenotype
Clinical studies
Cohort
Course
COVID-19
Critically ill patient
demonstrated
Drug repurposing
evaluate
FDA-approved drugs
FIASMA
functional
hallmark
healthy controls
independent
inhibition
intensive care
intensive care patient
lipoprotein
membrane
molecular biology of critical care
molecular markers
multicenter
observational studies
Organ failure
pathophysiological
pathway
provide
RBC
red blood cell
response
SARS-COV-2 infection
serum
severe coronavirus disease
severe COVID-19
SMPD1
sphingolipid
sphingomyelin
sphingomyelinase
Strategy
Stress
subsequent
Support
the patient
treatment strategy
Trial
with COVID-19
[DOI] 10.3389/fimmu.2021.784989 PMC 바로가기 [Article Type] Immunology
[DOI] 10.3389/fimmu.2021.784989 PMC 바로가기 [Article Type] Immunology